摘要
目的探讨新诊断2型糖尿病患者给予利拉鲁肽联合甘精胰岛素治疗后随访12周疗效。方法选取新诊断2型糖尿病患者126例,随机分为观察组和对照组,观察组64例给予利拉鲁肽联合甘精胰岛素治疗,对照组62例给予甘精胰岛素,疗程12周,比较治疗前、治疗后6和12周疗效。结果两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹C肽、餐后2 h C肽、胰岛素抵抗指数和体质量指标治疗随访期间均有所下降,其中观察组治疗6、12周后上述水平又明显低于对照组(P<0.05),而胰岛素β细胞功能指数、高密度脂蛋白胆固醇显著高于对照组(P<0.05)。结论治疗随访12周,利拉鲁肽联合甘精胰岛素在降糖、调脂、降体质量和促进胰岛功能恢复等方面均显著优于单用甘精胰岛素,值得临床推广应用。
Objective To investigate the efficacy of peptides combined with insulin glargine for newly diagnosed type 2 diabetic patients for 12 week following-up. Methods 126 patients with newly diagnosed type 2 diabetes were selected in our hospital, and were divided into two groups. Observation group was given Liraglutide combined with insulin glargine,while control group was given insulin glargine only. The effect were compared after 6~12 week following-up. Results All glucose and insulin secretion indexes（FPG,PPG,HbA1c, FCP, PCP, HOMA-IR）, and body mass index（body mass, body mass index） decreased during treatment period, The above indexes in observation group were significantly lower than those of control group after treatment for 6~12 weeks, and HOMA- β and HDL-C levels increased significantly than those of control group（P〈0.05）. Conclusion After treatment with Liraglutide and insulin glargine for 12 weeks, lipid-lowering, hypoglycemic,reducing body mass and recovering islet function were significantly better than those of treatment with insulin glargine only.It is worthy of clinical application.
出处
《热带医学杂志》
CAS
2017年第1期96-99,共4页
Journal of Tropical Medicine
